We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
In its upcoming report, Ionis Pharmaceuticals (IONS - Free Report) is predicted by Wall Street analysts to post quarterly loss of -$1.21 per share, reflecting a decline of 83.3% compared to the same period last year. Revenues are forecasted to be $155.58 million, representing a year-over-year decrease of 31.5%.
The consensus EPS estimate for the quarter has been revised 0.8% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Ionis Pharmaceuticals metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Revenue- Total commercial revenue' to reach $127.06 million. The estimate points to a change of +47.8% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Total research and development revenue' should arrive at $24.74 million. The estimate indicates a year-over-year change of -82.5%.
Analysts predict that the 'Revenue- Commercial revenue- Other commercial revenue' will reach $7.17 million. The estimate points to a change of -40.3% from the year-ago quarter.
The consensus estimate for 'Revenue- Commercial revenue- Other commercial revenue- TEGSEDI and WAYLIVRA revenue, net' stands at $7.17 million. The estimate indicates a year-over-year change of -10.4%.
The average prediction of analysts places 'Revenue- Research and development revenue- Collaborative agreement revenue' at $16.75 million. The estimate points to a change of -82.7% from the year-ago quarter.
Shares of Ionis Pharmaceuticals have demonstrated returns of +1.7% over the past month compared to the Zacks S&P 500 composite's -0.8% change. With a Zacks Rank #3 (Hold), IONS is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
In its upcoming report, Ionis Pharmaceuticals (IONS - Free Report) is predicted by Wall Street analysts to post quarterly loss of -$1.21 per share, reflecting a decline of 83.3% compared to the same period last year. Revenues are forecasted to be $155.58 million, representing a year-over-year decrease of 31.5%.
The consensus EPS estimate for the quarter has been revised 0.8% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Ionis Pharmaceuticals metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Revenue- Total commercial revenue' to reach $127.06 million. The estimate points to a change of +47.8% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Total research and development revenue' should arrive at $24.74 million. The estimate indicates a year-over-year change of -82.5%.
Analysts predict that the 'Revenue- Commercial revenue- Other commercial revenue' will reach $7.17 million. The estimate points to a change of -40.3% from the year-ago quarter.
The consensus estimate for 'Revenue- Commercial revenue- Other commercial revenue- TEGSEDI and WAYLIVRA revenue, net' stands at $7.17 million. The estimate indicates a year-over-year change of -10.4%.
The average prediction of analysts places 'Revenue- Research and development revenue- Collaborative agreement revenue' at $16.75 million. The estimate points to a change of -82.7% from the year-ago quarter.
View all Key Company Metrics for Ionis Pharmaceuticals here>>>Shares of Ionis Pharmaceuticals have demonstrated returns of +1.7% over the past month compared to the Zacks S&P 500 composite's -0.8% change. With a Zacks Rank #3 (Hold), IONS is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .